Project Grant N000141410127

This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $581,105 to Creighton University to develop natural-based therapies for treating hearing loss caused by aminoglycoside antibiotics. The key focus is on designing, synthesizing, and testing piperlongumine derivatives that can better target the TRPV1 channel to protect hair cells and synapses...

The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $305,628 Project Grant under the CFDA 93.173 Research Related to Deafness and Communication Disorders program to Echogenesis Therapeutics Inc. The grant will fund the development of a cell-type-specific gene therapy approach to treat congenital hearing loss caused by mutations in the TOMT gene. Specifically, the project aims to: 1) determine effective dosages for hearing restoration, 2) establish the optimal...

This Cooperative Agreement award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $999,393.00 to support Investigational New Drug (IND)-enabling studies for a novel therapeutic targeting the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of Alcohol Use Disorder (AUD). The awardee, Stress Therapeutics, Inc., a for-profit company in San Diego, California, will manufacture and validate the test article,...

This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the federal Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $131,555 to Oregon Health & Science University (OHSU) for a 2-year period from July 1, 2025 to June 30, 2027. The project aims to investigate how noise-induced hearing loss (NIHL) affects the central auditory processing of natural sound categories in the auditory cortex. Key...

The National Institute of Nursing Research (NINR) awarded a $827,727 Project Grant under the Nursing Research program (CFDA 93.361) to The Regents of the University of California, San Francisco (UCSF) to develop and test an intervention program aimed at preventing noise-induced hearing loss among Native American adults. The 5-year project will evaluate the effectiveness of a peer-group discussion model and hearing protection training program delivered in partnership with a regional population at...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $358,245 Project Grant to the Massachusetts Eye And Ear Infirmary on May 15, 2024 for the project "IN SILICO SCREEN AND IN VIVO EVALUATION OF FDA-APPROVED DRUGS TO TREAT NOISE-INDUCED HEARING LOSS". The grant supports a two-year effort to screen FDA-approved drugs and evaluate the most promising compounds for their ability to protect against noise-induced hearing loss in cell...

This $369,806 Project Grant from the National Institutes of Health's National Institute on Deafness and Other Communication Disorders will fund research into objective screening tests for noise-induced hearing damage. The University of Wisconsin-Madison will investigate short- and long-term changes in cochlear, afferent, and efferent auditory system function due to noise exposure using otoacoustic emission-based assays of the middle ear muscle reflex and medial olivocochlear reflex....

This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) provides $1,811,052.00 to Manzanita Pharmaceuticals Inc. to conduct IND-enabling toxicology and safety studies for "Nervelight", a novel nerve imaging agent for use during prostate cancer radical prostatectomy procedures. The key products to be delivered under this 2-year project include: 1) non-GLP dose-range finding studies in dogs to determine the optimal dose and...

This Cooperative Agreement award from the National Institute on Aging (NIA) under CFDA 93.866 Aging Research provides $3,189,298 to Virogenics, Inc. to conduct long-term non-clinical toxicology studies on the investigational Alzheimer's disease drug candidate CMS121. The goal is to advance CMS121 to a Phase 2 clinical trial by generating critical safety data to support longer-term daily administration in patients with mild to moderate Alzheimer's disease. The award will fund a 6-month rat and...

The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $498,000 Project Grant under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to the University of Pittsburgh. The project aims to develop an ex-vivo porcine round window membrane (RWM) model to evaluate the transport of nanovesicles, including extracellular vesicles (exosomes), as a method for non-surgical delivery of therapeutics to the inner ear to treat and prevent hearing...